WallStSmart

Orthopediatrics Corp (KIDS)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 23155% more annual revenue ($56.58B vs $243.30M). NVS leads profitability with a 23.9% profit margin vs -16.3%. NVS earns a higher WallStSmart Score of 49/100 (D+).

KIDS

Hold

38

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 6.7Quality: 7.0
Piotroski: 4/9Altman Z: 1.30

NVS

Hold

49

out of 100

Grade: D+

Growth: 3.3Profit: 9.0Value: 3.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

KIDSUndervalued (+72.6%)

Margin of Safety

+72.6%

Fair Value

$62.94

Current Price

$16.92

$46.02 discount

UndervaluedFair: $62.94Overvalued
NVSSignificantly Overvalued (-62.1%)

Margin of Safety

-62.1%

Fair Value

$91.39

Current Price

$148.38

$56.99 premium

UndervaluedFair: $91.39Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

KIDS1 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$273.77B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
35.1%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

Areas to Watch

KIDS4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$472.22M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-11.7%2/10

ROE of -11.7% — below average capital efficiency

Free Cash FlowQuality
$-5.05M2/10

Negative free cash flow — burning cash

NVS4 concerns · Avg: 2.8/10
Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.223/10

Elevated debt levels

PEG RatioValuation
3.932/10

Expensive relative to growth rate

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : KIDS

The strongest argument for KIDS centers on Price/Book. Revenue growth of 13.3% demonstrates continued momentum.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bear Case : KIDS

The primary concerns for KIDS are EPS Growth, Market Cap, Return on Equity.

Bear Case : NVS

The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.

Key Dynamics to Monitor

KIDS profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.

KIDS carries more volatility with a beta of 1.01 — expect wider price swings.

KIDS is growing revenue faster at 13.3% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (49/100 vs 38/100), backed by strong 23.9% margins. KIDS offers better value entry with a 72.6% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Orthopediatrics Corp

HEALTHCARE · MEDICAL DEVICES · USA

OrthoPediatrics Corp. The company is headquartered in Warsaw, Indiana.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?